| Protocol Id | PI | Protocol Title | INDICATION | PHASE | Sponsor | CRO/ Other |
| CDAK539A12303 | Dr. Narendra Agrawal | Phase 3, Randomized, Double-Blind, Active-Control Study of Pelabresib (DAK539) and Ruxolitinib vs. Placebo and Ruxolitinib in Adult Patients with Myelofibrosis who are JAK inhibitor naive | MF | III | Novartis | N/A UPCOMING RGCI |